|
|||||
|
|
Propeptide big-endothelin,N-terminal-pro brain natriuretic peptide and mortality. The Ludwigshafen risk and cardiovascular health (LURIC) study |
|
| Authors: | Ingrid Gergei Bernhard K Krämer Hubert Scharnagl Tatjana Stojakovic Winfried März Ulrich Mondorf |
| Institution: | 1. Vth Department of Medicine, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany;2. Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Graz, Graz, Austria;3. Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Graz, Graz, Austria;4. Synlab Academy, Synlab Holding Deutschland GmbH, Mannheim and Augsburg, Germany;5. Department of Medicine, Division of Nephrology, Johann Wolfgang Goethe-University, Frankfurt am Main, Germany;6. UMHealthcare, Frankfurt am Main, Germany |
| Abstract: | Context: The endothelin system (Big-ET-1) is a key regulator in cardiovascular (CV) disease and congestive heart failure (CHF). Objectives: We have examined the incremental value of Big-ET-1 in predicting total and CV mortality next to the well-established CV risk marker N-Terminal Pro-B-Type Natriuretic Peptide (NT-proBNP). Methods: Big-ET-1 and NT-proBNP were determined in 2829 participants referred for coronary angiography (follow-up 9.9 years). Results: Big-ET-1 is an independent predictor of total, CV mortality and death due to CHF. Discussion: The conjunct use of Big-ET-1 and NT-proBNP improves the risk stratification of patients with intermediate to high risk of CV death and CHF. Conclusions: Big-ET-1improves risk stratification in patients referred for coronary angiography. |
| Keywords: | N-terminal-pro brain natriuretic peptide big endothelin-1 congestive heart failure cardiovascular mortality biomarker |